1. Greining og fyrsta meðferð lungnakrabbameins
Sjúklingur Lu greindist með kirtilkrabbamein í lungum og meinvörp í eitlum 26. ágúst 2005. Brotnám á vinstri neðri hálsi var framkvæmd 22. september 2005. Carboplatin ásamt taxotere var notað 4 sinnum eftir aðgerð. Þann 3. ágúst 2007, vegna fleiðruvökva, var staðfest að greiningin væri endurtekin og hún var meðhöndluð með Tarceva (fjöldi lota er óþekktur). Þann 8. janúar 2008 fannst krabbameinsframvindan við endurskoðunina og þá var Tarceva meðferð hætt og Libita meðferð hafin í 16 lotur. Á sama tíma fundust meinvörp í hryggjarliðum og 4 lotur af Zetai voru gerðar.
2. Í fyrsta skipti sem tekið er þátt í klínískum rannsóknum er ástandið undir stjórn.
In July 2010, Mr. Lu reexamined a large area of brain metastasis and found dozens of small lesions in the brain. He also tested positive for the EML4-ALK fusion gene at the University of Chicago School of Medicine. The whole brain radiation therapy was then used to control the lesions, and the second phase of crizotinib drug trial was started at St. Louis University Hospital. During the treatment, the condition was stably controlled, but a re-examination in May 2012 found that the cancer had progressed slightly, and the æxli was suspected to be resistant to crizotinib. He stopped crizotinib on July 18, 2012.
3. Í annarri klínísku rannsókninni hvarf æxlið augljóslega.
On August 6, 2012, Mr. Lu participated in the AP26113 drug klínísk rannsókn at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the æxli í heila decreased and became large.
4. Uppgötvaðu sjaldgæfar genstökkbreytingar og hlakka til að taka þátt í nýjum klínískum rannsóknum
Endurskoðun í júlí 2014 sýndi PET fyrir allan líkamann: Heilaskemmdir voru í grundvallaratriðum stöðugar og brjóstið hafði augljósar framfarir. Þann 12. maí 2014, voru ræktaðar frumulínur sem grunaðir eru um and-AP26113 (3 frumur, stærst 1.1 cm) framkvæmdar á Massachusetts General Hospital og héldu áfram að taka AP26113.
In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s taugaæxli and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.
On December 8, 2014, after a doctor’s analysis and decision, Mr. Lu was approved to increase the dosage of AP26113 and changed it to 240 mg per day, so the drug replacement plan was temporarily delayed. After observing the efficacy, he decided whether to change the drug and participate in other clinical trials. The patient learned through the hospital that NIVOLUMAB monoclonal antibody ónæmismeðferð phase 3/4 drug test is recruiting lung cancer patients on a large scale, and Mr. Lu is fully confident of the future anti-cancer.
